Holen Sie sich die Stockscreener-App
135.37
1.39%
1.85
Handel nachbörslich:
135.37
Schlusskurs vom Vortag:
$133.52
Offen:
$132.36
24-Stunden-Volumen:
807.82K
Relative Volume:
1.07
Marktkapitalisierung:
$7.95B
Einnahmen:
$551.35M
Nettoeinkommen (Verlust:
$-189.33M
KGV:
-41.13
EPS:
-3.2916
Netto-Cashflow:
$-35.09M
1W Leistung:
-0.35%
1M Leistung:
+16.30%
6M Leistung:
+50.60%
1J Leistung:
+50.48%
1-Tages-Spanne:
$130.64
$136.26
1-Wochen-Bereich:
$130.04
$137.87
52-Wochen-Spanne:
$73.16
$146.75
Glaukos Corp Stock (GKOS) Company Profile
Firmenname
Glaukos Corp
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
135.37 | 7.84B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corp Aktie (GKOS) Neueste Nachrichten
[144] GLAUKOS Corp SEC Filing - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Number of shareholders of Glaukos Corp – LS:A14VCK - TradingView
Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile - AD HOC NEWS
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
Glaukos Corp. Hits New 52-Week High at $145.50, Reflecting Strong Growth - Markets Mojo
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares By Investing.com - Investing.com South Africa
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares - Investing.com Nigeria
Glaukos president & COO Gilliam sells $2.8m in company stock - Investing.com Australia
Glaukos president & COO Gilliam sells $2.8m in company stock By Investing.com - Investing.com South Africa
Glaukos (GKOS) CFO exercises options and sells 10,000 shares under plan - Stock Titan
GLAUKOS (GKOS) President & COO sells 19,573 shares in open-market trade - Stock Titan
GLAUKOS (GKOS) director Leana Wen sells 1,700 shares, holds 19,739 - Stock Titan
Glaukos Corp Leads Innovation in Chronic Eye Disease Treatment with iDose TR and Epioxa Therapies – 2026 Investor Update - Minichart
Glaukos to present May 2026 investor slide deck highlighting iDose TR, Epioxa launch and 2026 guidance - TradingView
[8-K] GLAUKOS Corp Reports Material Event - Stock Titan
How The Glaukos (GKOS) Narrative Is Shifting With New Guidance And Product Ramp Expectations - Yahoo Finance
UBS Group AG Increases Position in Glaukos Corporation $GKOS - MarketBeat
MSN - MSN
Earnings Update: Here's Why Analysts Just Lifted Their Glaukos Corporation (NYSE:GKOS) Price Target To US$148 - Sahm
Glaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Glaukos Corp. Earnings Call Signals Growth Momentum - The Globe and Mail
Glaukos Up Over 19%, On Track for Largest Percent Increase Since December 2023 -- Data Talk - Moomoo
Fidelity Brokerage Services LLC (GKOS) files Form 144 to sell 19,573 shares - Stock Titan
GKOS SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
MSN Money - MSN
GKOS Maintains Overweight Rating by JP Morgan -- Price Target Ra - GuruFocus
GKOS Maintained by Citigroup -- Price Target Raised to $140 - GuruFocus
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
Glaukos (GKOS) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Glaukos stock reaches 52-week high at $143.81 By Investing.com - Investing.com Canada
GKOS Maintained by Wells Fargo -- Price Target Raised to $138.00 - GuruFocus
Midday Stock Roundup: Alignment Healthcare Shares Fall 12% Following Q1 Earnings - Orange County Business Journal
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook - Zacks Investment Research
Glaukos Stock Surges 18% on Record Q1 Sales Beat and Raised 2026 Outlook as iDose TR Demand Soars - International Business Times Australia
GKOS Maintained by BTIG -- Price Target Raised to $141.00 - GuruFocus
GKOS Maintained by Needham -- Price Target Raised to $136 - GuruFocus
Glaukos (GKOS) Rule 144: Fidelity lists 10,000‑share resale, insider trades - Stock Titan
Glaukos (NYSE:GKOS) Sets New 1-Year High After Earnings Beat - MarketBeat
Glaukos stock reaches 52-week high at $143.81 - Investing.com
Wells Fargo & Company Raises Glaukos (NYSE:GKOS) Price Target to $138.00 - MarketBeat
Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript - Insider Monkey
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock - MarketBeat
Needham raises Glaukos stock price target to $136 on revenue beat By Investing.com - Investing.com South Africa
Needham raises Glaukos stock price target to $136 on revenue beat - Investing.com Australia
GLAUKOS Corp 1Q 2026: Revenue $150.6M, EPS $(0.34) — 10-Q Summary - TradingView
BTIG raises Glaukos stock price target to $141 on strong results - Investing.com
Finanzdaten der Glaukos Corp-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):